0001193125-14-200354.txt : 20140515 0001193125-14-200354.hdr.sgml : 20140515 20140515101909 ACCESSION NUMBER: 0001193125-14-200354 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20140514 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140515 DATE AS OF CHANGE: 20140515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TECHNE CORP /MN/ CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 14844456 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 8-K 1 d728502d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 14, 2014

 

 

TECHNE CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Minnesota   0-17272   41-1427402

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

614 McKinley Place N.E.

Minneapolis, MN 55413

(Address of Principal Executive Offices)(Zip Code)

(612) 379-8854

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 14, 2014, the Board of Directors (the “Board”) of Techne Corporation (the “Company”) elected Harold J. Wiens as a member of the Board effective as of May 15, 2014.

It is expected that Mr. Wiens will be appointed to the Nominations and Governance Committee and the Audit Committee.

Mr. Wiens, 68, is a 30 plus year veteran of 3M Company (“3M”). Mr. Wiens began his 3M career in 1968 and held multiple domestic and international engineering and production management roles, including Memory Technologies Group Manufacturing Manager for the Europe location, Managing Director and Executive Vice President of Sumitomo 3M, and, most recently, Executive Vice President of 3M’s Industrial Sector. Prior to retiring from 3M in 2006, under 3M’s first external CEO, Mr. Wiens restructured the business and led a global implementation of Six Sigma, which together resulted in faster business processes and a focus on customers that drove international growth. Since retirement, he remains active in the community by serving on the boards of local non-profit entities such as Bethel University and Presbyterian Homes and Services. Mr. Wiens holds a Bachelor’s degree in mechanical engineering from Michigan Technological University.

As a non-employee director, Mr. Wiens will be eligible to receive an annual fee of $40,000 and will be eligible to receive an annual grant of an option to purchase 4,000 shares of Company common stock and 1,000 shares of Company restricted stock. For his service during a portion of fiscal 2014, Mr. Wiens will receive a stock option to purchase 2,000 shares of Company common stock and 500 shares of Company restricted stock. All such options will have an exercise price equal to the closing price of the Company’s common stock on the date of grant, and the risk of forfeiture for all such shares of Company restricted stock will lapse one year after the date of grant.

 

Item 8.01 Other Events

On May 15, 2014, the Company issued a press release announcing the appointment of Mr. Wiens to the Company’s Board of Directors. A copy of the press release is attached hereto as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits.

 

  (a) Financial statements: None.

 

  (b) Pro forma financial information: None.

 

  (c) Shell company transactions: None.

 

  (d) Exhibits:

 

99.1    Press Release dated May 15, 2014.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Techne Corporation
Date: May 15, 2014     By   /s/ Charles R. Kummeth
    Name:   Charles R. Kummeth
    Title:   Chief Executive Officer


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

TECHNE CORPORATION

EXHIBIT INDEX TO FORM 8-K

 

Date of Report:    Commission File No.:
May 15, 2014    0-17272

 

Exhibit Number    Description
99.1    Press Release dated May 15, 2014.
EX-99.1 2 d728502dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

BIO-TECHNE ANNOUNCES THE APPOINTMENT OF HAROLD WIENS

TO THE BOARD OF DIRECTORS

Minneapolis/May 15, 2014/ Techne Corporation (NASDAQ:TECH) (d/b/a Bio-Techne) announces that Harold Wiens, a 30+ year veteran of 3M company, has joined the board of Bio-Techne, adding additional seasoned global business experience to a well-established team.

Harold graduated from Michigan Technological University with a Bachelor’s degree in Mechanical Engineering in 1968. He began working for 3M in St Paul, and in 1968 moved to California to work in the Data Recording Products Division factory in Camarillo. Over the next 15 years, he moved through several engineering and production management assignments and was appointed in 1983 as the Memory Technologies Group Manufacturing Manager for Europe, headquartered in Brussels, Belgium.

Harold returned to the U.S. in 1988 and was appointed as Department Manager of the Data Cartridge business. In 1992 he became the Vice President of the rapidly growing Data Tape Division. Then, in 1995 he was appointed Managing Director and Executive Vice President of Sumitomo 3M, the company’s largest subsidiary, headquartered in Tokyo, Japan. In 1998 he was appointed Executive Vice President of 3M’s Industrial Business which, at the time, had sales of just over $3B. Over the next five years, working under 3M’s first external CEO, Jim McNerney, Harold restructured the business and led a global implementation of Six Sigma which together resulted in faster business processes and a focus on customers that drove international growth. Today, the Industrial Segment is still the largest in 3M with annual revenues over $10B. Harold retired from 3M in 2006, remaining active in the community serving on the boards of local non- profit entities such as Bethel University and Presbyterian Homes and Services.

“Harold brings amazing attributes and experiences to our board at a critical time as we expand the company globally and drive customer focus and innovation. Harold is deeply knowledgeable in international business practices and, as we drive growth and more innovation here at Bio-Techne, he will be instrumental in guiding balance between operations and accelerated growth,” stated Bio-Techne President and CEO, Chuck Kummeth.

* * * * * * * * * * * * * *

Techne Corporation (d/b/a Bio-Techne) is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With over 24,000 products in its portfolio, Bio-Techne generated approximately $311M in net sales in FY 2013 and has over 1,000 employees globally. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.

Contact:

Chuck Kummeth

Chief Executive Officer

(612) 379-8854